AP NEWS

Chronic Stable Angina - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 22, 2019

DUBLIN--(BUSINESS WIRE)--Jan 22, 2019--The “Chronic Stable Angina - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Stable Angina development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Chronic Stable Angina

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Chronic Stable Angina

The report assesses the active Chronic Stable Angina pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

AstraZeneca Pfizer Sinphar Pharmaceutical Co. Ltd. Bayer AstraZeneca Amgen Chong Kun Dang Pharmaceutical Euro CTO Club

Topics Covered

1. Report Introduction

2. Chronic Stable Angina Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical & Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cc769d/chronic_stable?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005476/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/22/2019 06:54 AM/DISC: 01/22/2019 06:54 AM

http://www.businesswire.com/news/home/20190122005476/en

AP RADIO
Update hourly